Renal denervation in internal medicine: a FADOI Position Paper on behalf of the Vicenza Hypertension Multidisciplinary Team. Endorsed by the Italian Society of Arterial Hypertension
Abstract
Resistant hypertension (RH) remains a clinical challenge in internal medicine, associated with increased cardiovascular morbidity and mortality. Renal denervation (RDN), a catheter-based intervention targeting renal sympathetic nerves, has re-emerged as a promising “adjunctive” therapy following the publication of the latest sham-controlled randomized trials. Current data demonstrate that RDN provides a modest but consistent reduction in blood pressure, with a favorable safety profile in selected patients with RH and uncontrolled hypertension, despite optimized pharmacological therapy or in those with medication intolerance. This paper reviews the pathophysiological rationale, updated clinical evidence, patient selection criteria, procedural aspects, and future perspectives of RDN, for which a multidisciplinary approach is required to ensure procedural safety and optimal outcomes.
This position paper is not intended to be a new guideline but a practical recommendation on how to proceed with the selection of the patient candidate for RDN and his management before and after the procedure in internal medicine coordinated by a hypertension specialist.
Related
- Renal Denervation for Hypertension ― Mechanisms, Evidence, and Clinical Integration ―
- Renal denervation beyond resistant hypertension: should drug intolerance redefine eligibility?
- Clinical Effect of Renal Denervation on Resistant Hypertension in Obese and Nonobese Patients: Insights from Kuwait
- SFAR's position: Organization of perinatal care in anesthesia, critical care, and perioperative medicine in France
- Evaluation of an Internal Medicine Resident Research Program and Barriers to Research at an Academic Medical Center
BibTeX
@article{mazza2026renal,
title = {{Renal denervation in internal medicine: a FADOI Position Paper on behalf of the Vicenza Hypertension Multidisciplinary Team. Endorsed by the Italian Society of Arterial Hypertension}},
author = {Alberto Mazza and Luca Rossi and Claudio Bilato and Giovanni Morani and Monica Zanella and Vincenzo Iurilli and Vinicio Danzi and Alberto Rigo and Fabio Presotto and Dario Manfellotto and Agostino Virdis and Alessandra Violet Bacca and Giovambattista Desideri and Maria Lorenza Muiesan and Francesco Dentali and Andrea Montagnani},
journal = {Italian Journal of Medicine},
year = {2026},
month = oct,
doi = {10.4081/itjm.2026.2633},
url = {https://doi.org/10.4081/itjm.2026.2633},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Renal denervation in internal medicine: a FADOI Position Paper on behalf of the Vicenza Hypertension Multidisciplinary Team. Endorsed by the Italian Society of Arterial Hypertension
AU - Alberto Mazza
AU - Luca Rossi
AU - Claudio Bilato
AU - Giovanni Morani
AU - Monica Zanella
AU - Vincenzo Iurilli
AU - Vinicio Danzi
AU - Alberto Rigo
AU - Fabio Presotto
AU - Dario Manfellotto
AU - Agostino Virdis
AU - Alessandra Violet Bacca
AU - Giovambattista Desideri
AU - Maria Lorenza Muiesan
AU - Francesco Dentali
AU - Andrea Montagnani
PY - 2026
DA - 2026/10/23
JO - Italian Journal of Medicine
DO - 10.4081/itjm.2026.2633
UR - https://doi.org/10.4081/itjm.2026.2633
AB - Resistant hypertension (RH) remains a clinical challenge in internal medicine, associated with increased cardiovascular morbidity and mortality. Renal denervation (RDN), a catheter-based intervention targeting renal sympathetic nerves, has re-emerged as a promising “adjunctive” therapy following the publication of the latest sham-controlled randomized trials. Current data demonstrate that RDN provides a modest but consistent reduction in blood pressure, with a favorable safety profile in selected patients with RH and uncontrolled hypertension, despite optimized pharmacological therapy or in those with medication intolerance. This paper reviews the pathophysiological rationale, updated clinical evidence, patient selection criteria, procedural aspects, and future perspectives of RDN, for which a multidisciplinary approach is required to ensure procedural safety and optimal outcomes. This position paper is not intended to be a new guideline but a practical recommendation on how to proceed with the selection of the patient candidate for RDN and his management before and after the procedure in internal medicine coordinated by a hypertension specialist.
SN - 1877-9344
SN - 1877-9352
ER -